Eaton Financial Holdings Company LLC Acquires New Position in Pfizer Inc. $PFE

Key Points

• Eaton Financial Holdings has acquired a new position in Pfizer, purchasing 23,671 shares valued at approximately $574,000 in the second quarter.
• Analysts have set new price targets for Pfizer, with a consensus rating of "Hold" and an average target price of $28.12.
• Pfizer announced a quarterly dividend of $0.43, representing an annualized yield of 7.2%, with a dividend payout ratio of 91.49%.

Eaton Financial Holdings Company LLC bought a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 23,671 shares of the biopharmaceutical company's stock, valued at approximately $574,000.

Several other institutional investors and hedge funds have also modified their holdings of PFE. GKV Capital Management Co. Inc. bought a new position in Pfizer during the first quarter valued at approximately $27,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the 1st quarter worth $28,000. North Capital Inc. acquired a new position in shares of Pfizer during the 1st quarter worth $28,000. Bernard Wealth Management Corp. bought a new position in shares of Pfizer during the 4th quarter valued at $30,000. Finally, WPG Advisers LLC acquired a new stake in shares of Pfizer in the 1st quarter valued at $35,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on PFE shares. Morgan Stanley increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Berenberg Bank lowered their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a report on Saturday. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Bank of America lifted their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Price Performance

Shares of Pfizer stock opened at $24.05 on Tuesday. The firm has a market cap of $136.74 billion, a P/E ratio of 12.79, a price-to-earnings-growth ratio of 0.78 and a beta of 0.55. The firm's 50-day simple moving average is $24.61 and its 200-day simple moving average is $24.18. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter last year, the company earned $0.60 earnings per share. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.